| 1 |
34873089 | Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. | 2022 Mar 15 |
1 |
| 2 |
35099526 | Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. | 2022 Mar 1 |
1 |
| 3 |
35115810 | The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics. | 2022 |
2 |
| 4 |
35194103 | CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. | 2022 Feb 22 |
1 |
| 5 |
35235559 | Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya. | 2022 |
2 |
| 6 |
35512066 | The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. | 2022 Apr 29 |
1 |
| 7 |
32667979 | Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens. | 2021 May 18 |
1 |
| 8 |
32815870 | Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. | 2021 Jan |
1 |
| 9 |
32829410 | Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. | 2021 Oct 5 |
5 |
| 10 |
32909316 | Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. | 2021 Apr |
1 |
| 11 |
32960272 | CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. | 2021 Dec 6 |
4 |
| 12 |
33336382 | Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. | 2021 Jun |
1 |
| 13 |
33599403 | Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population. | 2021 Mar |
1 |
| 14 |
33758532 | Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. | 2021 |
3 |
| 15 |
33833550 | Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]. | 2021 |
1 |
| 16 |
33872945 | Identification of miRNAs that regulate human CYP2B6 expression. | 2021 Jun |
2 |
| 17 |
34093191 | Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy. | 2021 |
2 |
| 18 |
34115651 | Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. | 2021 Oct 1 |
3 |
| 19 |
34415664 | Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. | 2021 Nov |
1 |
| 20 |
34474119 | Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. | 2021 Dec 1 |
6 |
| 21 |
34882770 | Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). | 2021 Nov 19 |
2 |
| 22 |
34945777 | Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. | 2021 Dec 5 |
2 |
| 23 |
31628422 | Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. | 2020 Apr |
5 |
| 24 |
32106141 | Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. | 2020 Apr |
6 |
| 25 |
32377759 | Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6? | 2020 Aug |
1 |
| 26 |
32451120 | Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. | 2020 Jul |
4 |
| 27 |
32838647 | Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. | 2020 Aug |
1 |
| 28 |
33355828 | Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy. | 2020 Dec |
3 |
| 29 |
30535366 | Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. | 2019 Mar 1 |
1 |
| 30 |
31006110 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. | 2019 Oct |
3 |
| 31 |
31241542 | Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. | 2019 Aug 1 |
2 |
| 32 |
31243456 | Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. | 2019 Sep 1 |
1 |
| 33 |
31299074 | Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. | 2019 Oct 1 |
2 |
| 34 |
31324697 | Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. | 2019 Oct |
20 |
| 35 |
29629676 | A proposed management algorithm for late-onset efavirenz neurotoxicity. | 2018 Mar 28 |
2 |
| 36 |
29635009 | The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy. | 2018 Jul 1 |
1 |
| 37 |
29636682 | Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. | 2018 |
1 |
| 38 |
29855606 | Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. | 2018 Sep |
1 |
| 39 |
29868865 | Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. | 2018 Sep 1 |
1 |
| 40 |
30201214 | Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. | 2018 Oct |
4 |
| 41 |
27799204 | Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. | 2017 Jan |
1 |
| 42 |
28403028 | Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. | 2017 Jul |
1 |
| 43 |
28481785 | Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana. | 2017 Aug 1 |
2 |
| 44 |
28559276 | Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. | 2017 Aug |
1 |
| 45 |
28718515 | Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. | 2017 Sep |
1 |
| 46 |
26553012 | In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. | 2016 Jan |
3 |
| 47 |
26655325 | CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. | 2016 Jun |
2 |
| 48 |
26831894 | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. | 2016 Feb 2 |
1 |
| 49 |
26891286 | Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. | 2016 Feb 16 |
2 |
| 50 |
27045425 | CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. | 2016 Apr |
2 |